Chou, Chao-Kai

PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression

Jiao, S., Xia, W., Yamaguchi, H., Wei, Y., Chen, M.-K., Hsu, J.-M., Hsu, J. L., Yu, W.-H., Du, Y., Lee, H.-H., et al. (2017) · Clinical Cancer Research

PARP inhibition in cancer therapyCancer Immunotherapy and Biomarkers

Cited by 981

Human insulin receptors mutated at the ATP-binding site lack protein tyrosine kinase activity and fail to mediate postreceptor effects of insulin.

Chou, C. K., Dull, T. J., Russell, D. S., Gherzi, R., Lebwohl, D., Ullrich, A., & Rosen, O. M. (1987) · Journal of Biological Chemistry

Metabolism, Diabetes, and CancerProtein Kinase Regulation and GTPase Signaling

Cited by 640

KEAP1 E3 Ligase-Mediated Downregulation of NF-κB Signaling by Targeting IKKβ

Lee, D.-F., Kuo, H.-P., Liu, M., Chou, C.-K., Xia, W., Du, Y., Shen, J., Chen, C.-T., Huo, L., Hsu, M.-C., et al. (2009) · Molecular Cell

NF-κB Signaling PathwaysUbiquitin and proteasome pathways

Cited by 399

PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response.

Liao, H.-W., Hsu, J.-M., Xia, W., Wang, H.-L., Wang, Y.-N., Chang, W.-C., Arold, S. T., Chou, C.-K., Tsou, P.-H., Yamaguchi, H., et al. (2015) · Journal of Clinical Investigation

HER2/EGFR in Cancer ResearchCancer-related gene regulation

Cited by 155